Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?

Published:2024-09 Issue:9 Volume:17 Page:102512
ISSN:1876-0341
Container-title:Journal of Infection and Public Health
language:en
Short-container-title:Journal of Infection and Public Health

Author:

Bang Line Lundegaard,Madsen Lone Wulff,Pedersen Rune Micha,Nilsson Anna Christine,Johansen Isik Somuncu^ORCID,Andersen Thomas Emil

Funder

Region of Southern Denmark

Publisher

Elsevier BV

Reference12 articles.

1. Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2;Behzad;J Infect Public Health,2024

2. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review;Drysdale;Infection,2024

3. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies;Wilhelm;eBioMedicine,2022

4. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2;Uraki;Nature,2022

5. Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model;Hérate;Heliyon,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP